We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment. Initial therapy (leuprolide or DES) was continued for as long as an objective response was noted; cross-over to the alternative arm occurred at the time of disease progression or intolerable adverse reactions. Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES. Suppression of testosterone and dihydrotestosterone and decreases in acid phosphatase were comparable in the two groups. Patients receiving DES experienced more frequent painful gynecomastia (P less than 0.00001), nausea and vomiting (P = 0.02), edema (P = 0.008), and thromboembolism (P = 0.065) than those receiving leuprolide. The leuprolide group reported more "hot flashes" (P = 0.00001). Overall, 86 per cent of the leuprolide group had an objective response (complete response, 1 per cent; partial response, 37 per cent; stable disease, 48 per cent), as compared with 85 per cent of the DES group (complete, 2 per cent; partial, 44 per cent; stable, 39 per cent). Actual survival rates at one year were 87 per cent for the leuprolide group and 78 per cent for the DES group (P = 0.17). We conclude that leuprolide offers an important alternative treatment that is therapeutically equivalent to and causes fewer side effects than DES for the initial systemic management of metastatic prostate cancer.
This article has been cited by other articles:
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., Smith, M. R.
(2008). Management of Complications of Prostate Cancer Treatment. CA Cancer J Clin
58: 196-213
[Abstract][Full Text]
Smith, M. R.
(2007). Obesity and Sex Steroids during Gonadotropin-Releasing Hormone Agonist Treatment for Prostate Cancer. Clin. Cancer Res.
13: 241-245
[Abstract][Full Text]
Naito, S.
(2005). Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer. Jpn J Clin Oncol
35: 365-374
[Abstract][Full Text]
Harrison, G S, Wierman, M E, Nett, T M, Glode, L M
(2004). Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer
11: 725-748
[Abstract][Full Text]
Taxel, P., Fall, P. M., Albertsen, P. C., Dowsett, R. D., Trahiotis, M., Zimmerman, J., Ohannessian, C., Raisz, L. G.
(2002). The Effect of Micronized Estradiol on Bone Turnover and Calciotropic Hormones in Older Men Receiving Hormonal Suppression Therapy for Prostate Cancer. J. Clin. Endocrinol. Metab.
87: 4907-4913
[Abstract][Full Text]
Hellerstedt, B. A., Pienta, K. J.
(2002). The Current State of Hormonal Therapy for Prostate Cancer. CA Cancer J Clin
52: 154-179
[Abstract][Full Text]
Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y.-J., Vincelette, A., Greenspan, S. L.
(2001). Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists. J. Clin. Endocrinol. Metab.
86: 2787-2791
[Abstract][Full Text]
Seidenfeld, J., Samson, D. J., Hasselblad, V., Aronson, N., Albertsen, P. C., Bennett, C. L., Wilt, T. J.
(2000). Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. ANN INTERN MED
132: 566-577
[Abstract][Full Text]
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., Trump, D.
(1999). Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer. NEJM
341: 1781-1788
[Abstract][Full Text]
Garnick, M. B., Eisenberger, M., Blumenstein, B. A.
(1999). Hormonal Treatment of Prostate Cancer. NEJM
340: 812-813
[Full Text]
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., Lowe, B. A.
(1998). Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer. NEJM
339: 1036-1042
[Abstract][Full Text]
DiPaola, R. S., Zhang, H., Lambert, G. H., Meeker, R., Licitra, E., Rafi, M. M., Zhu, B. T., Spaulding, H., Goodin, S., Toledano, M. B., Hait, W. N., Gallo, M. A.
(1998). Clinical and Biologic Activity of an Estrogenic Herbal Combination (PC-SPES) in Prostate Cancer. NEJM
339: 785-791
[Abstract][Full Text]
(1996). Estrogen Therapy for Prostate Carcinoma. JAMA
275: 1153-1153
Catalona, W. J.
(1994). Management of Cancer of the Prostate. NEJM
331: 996-1004
[Full Text]
Wood, B. C
(1993). Review article : Hormone treatments in the common 'hormone-dependent' carcinomas. Palliat Med
7: 257-272
[Abstract]
Scholtz, J. M.
(1991). General Principles and Pharmacology of Antineoplastic Agents. Journal of Pharmacy Practice
4: 3-10
VANCE, M. L., THORNER, M. O.
(1986). Growth-Hormone-Releasing Hormone: A Clinical Update. ANN INTERN MED
105: 447-449
[Abstract]
Glode, L. M., Smith, J. A.
(1985). LHRH. JAMA
254: 506-507
[Abstract]
Previous
